查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年连续血糖监测的全球市场
市场调查报告书
商品编码
776946

2022-2029 年连续血糖监测的全球市场

Global Continuous Glucose Monitoring Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球持续血糖监测市场的增长是由对预防性糖尿病护理、新产品发布和政府支持措施的认识不断提高推动的。开发新颖且技术先进的 CGM 已成为血糖监测设备製造商的主要关注点。它为所有年龄段和医疗保健环境提供了广泛的应用。

连续血糖监测 (CGM) 设备的日益普及将推动市场增长

对于依赖胰岛素泵或每日註射胰岛素的患者，连续血糖监测 (CGM) 是一种有用的工具，可在不增加致命低血糖风险的情况下增强血糖平衡。建立自己。多项临床试验表明，1 型糖尿病（T1DM）患者在使用持续血糖监测时的血糖控制优于每日使用血糖仪自我监测血糖。这种趋势在儿童和定期使用连续血糖监测 (CGM) 的患者中是相似的。这些儿童的结果显示出更好的糖化血红蛋白 (HbA1c) 水平，而没有增加低血糖发生率。

目前已获批准的连续血糖监测 (CGM) 模型使用基于葡萄糖氧化□的电化学皮下传感器来检测间质液中的葡萄糖水平。连续血糖监测 (CGM) 设备包括通过下载数据回顾显示血糖趋势，以及提供实时血糖水平的接收器显示器。大多数实时连续血糖监测 (CGM) 设备可以在实际或待定血糖访问期间提醒患者、父母或护理人员，以便及时控制血糖水平。我可以做到。然而，连续血糖监测 (CGM) 设备缺乏准确性、需要频繁校准以及医疗保险报销的不一致是製约市场增长的主要因素。

缺乏适当的设备报销阻碍了市场增长

但是，缺乏足够的设备报销仍然是设备采用的主要障碍。这种缺乏报销的可能是由于该设备被 FDA 批准为标准家用血糖仪的辅助疗法。在美国等地进行报销时，只有特定的患者群体才能获得符合严格适应症的报销。鑑于临床试验已证明使用 CGM 是有益的，这种情况有些令人惊讶。

COVID-19 影响分析

在 COVID-19 大流行期间，随着联邦机构放宽限制并发布在医院环境中使用家用血糖仪或 CGM 的指南，对连续血糖监测设备的需求正在增加Nicole Ehrhardt 等人于 2020 年 11 月在糖尿病护理杂誌上发表的一项研究发现，COVID-19 大流行需要在医院持续监测血糖，以保存个人防护设备 (PPE) 并限制医护人员的接触。评估监测（CGM）可行性的新需求。此外，7.8–10.0 mmol/L (140–180 mg/dL) 的血糖控制在许多医院对 ICU 和非 ICU 区域的 COVID-19 感染者来说是一个挑战。

根据 Sandip Garg 等人的一项研究，据说它承受着相当大的财务压力。糖尿病护理是大流行和技术在改变医疗保健提供方面日益重要的融合的一个例子。在大流行期间，COVID-19 给美国带来的直接医疗保健成本估计在 1600 亿美元（感染人口的 20%）和 6500 亿美元（感染人口的 80%）之间。 COVID-19 的流行凸显了糖尿病患者对良好血糖控制的需求。这是因为大多数观察性研究报告说，糖尿病控制不佳与因病毒性疾病而住院和死亡的风险增加有关。

本研究报告将提供对全球连续血糖监测市场大约 40 多个市场数据表、45 多个数字和 200 多页（大约）的访问权限。

内容

第 1 章全球连续血糖监测市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章全球连续血糖监测市场 - 市场定义和概述

第 3 章全球连续血糖监测市场-执行摘要

  • 按组件划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章全球连续血糖监测市场 - 市场动态

  • 市场影响因子
    • 驱动程序
      • 越来越多地采用连续血糖监测 (CGM) 设备
      • 糖尿病患者增加
    • 约束因素
      • 医疗保险报销不一致
    • 商机
    • 影响分析

第 5 章全球连续血糖监测市场-行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章全球持续血糖监测市场 - COVID-19 分析

  • 对 COVID-19 市场的分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章全球连续血糖监测市场 - 按组件

  • 发射器
  • 接收者
  • 传感器
  • 胰岛素泵
  • 其他

第 8 章全球持续血糖监测市场 - 按最终用户分类

  • 诊断中心
  • 重症监护室
  • 家庭保健

第 9 章全球连续血糖监测市场 - 按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章全球连续血糖监测市场 - 竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 11 章全球连续血糖监测市场 - 公司简介

  • Abbott Laboratories
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Dexcom, Inc.
  • A. Menarini Diagnostics s.r.l
  • Echo Therapeutics, Inc.
  • GlySens Incorporated
  • Johnson and Johnson
  • Medtronic Plc
  • Senseonics Holdings, Inc.
  • F. Hoffmann-La Roche Ltd
  • Medtrum Technologies, Inc.

第 12 章全球连续血糖监测市场 - DataM

简介目录
Product Code: DMMD699

Market Overview

The Global "Continuous Glucose Monitoring Market" is expected to grow at a high CAGR of 22.0% during the forecast period (2022-2029).

Continuous Glucose Monitoring (CGM) devices are the advancement in diabetes management, where the blood glucose is under continuous monitor. The introduction of CGM devices integrated with insulin pumps using transmitters, receivers, and glucose sensors also increased their adoption due to improved convenience. The process of data collection through CGM has helped people keep track of their daily glucose levels.

Market Dynamics

The global continuous glucose monitoring market growth is driven by the growing awareness about diabetes preventive care, new product launches, and supportive government initiatives. The development of novel and technologically advanced CGM is the prime focus of glucose monitoring device manufacturing companies. It offers a wide range of applications for all age-cohorts, healthcare settings.

Increasing adoption of continuous glucose monitoring (CGM) devices will drive the market growth

The patients reliant on insulin pumps or daily insulin injections, continuous glucose monitoring (CGM) establishes itself to be an instrumental tool, which helps in the enhancement of glycemic balance without increasing the danger of fatal hypoglycemia. As studied in several clinical trials, diabetic patients with Type 1 diabetes mellitus (T1DM) using continuous glucose monitoring have shown to have better glycemic control, in comparison to when glucometer is used for routine self-monitoring blood glucose. The trend follows in children, as well as those who use continuous glucose monitoring (CGM) on a regular basis. The results in these children show better-glycosylated hemoglobin (HbA1c) levels without an amplified frequency of hypoglycemia.

The current continuous glucose monitoring (CGM) models approved administer glucose oxidase-based electrochemical subcutaneous sensors for the detection of glucose levels in the interstitial fluid. Continuous glucose monitoring (CGM) devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. Most of the real-time continuous glucose monitoring (CGM) devices can offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, to facilitate timely management of blood glucose. However, lack of accuracy of continuous glucose monitoring (CGM) devices, need for frequent calibration, and inconsistency of medicare reimbursement are the major factors restraining the market growth.

Lack of adequate reimbursement for devices will hamper the market growth

However, lack of adequate reimbursement for devices is the key barrier to the adoption of the devices. This lack of coverage is likely due to the devices receiving FDA approval as adjunctive therapy to standard home blood glucose monitors. In case reimbursement is in a place like in the United States, only certain patient groups get the reimbursement that fulfills strict indications. This situation is somewhat surprising in view of the mounting evidence for benefits of CGM usage from clinical trials.

COVID-19 Impact Analysis

Increased demand for continuous glucose monitoring devices amid the COVID-19 pandemic is attributed to the loosened restricted regulations and issued guidelines for the use of home-use glucose meters or CGMs in hospital settings by the federal agencies. According to the research study by Nicole Ehrhardt et al., published in Diabetes Care Journal November 2020, the COVID-19 pandemic has brought a new urgency to the need to assess the feasibility of continuous glucose monitoring (CGM) in the hospital to preserve personal protective equipment (PPE) and limit health care worker's exposure. Moreover, glycemic control of 7.8-10.0 mmol/L (140-180 mg/dL) is a challenge for many hospitals in both the ICU and non-ICU areas for those infected with COVID-19.

According to a research study by Sandip Garg et al., published in Diabetes Technology & Therapeutics Journal March 2021, the COVID-19 pandemic has exposed vulnerabilities and placed tremendous financial pressure on nearly all aspects of the United States health care system. Diabetes care is an example of the confluence of the pandemic and heightened importance of technology in changing care delivery. It has been estimated the added total direct United States medical cost burden due to COVID-19 to range between USD 160B (20% of the population infected) and USD 650B (80% of the population infected) over the course of the pandemic. The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, in large part because most observational studies have reported poorly controlled diabetes is associated with a higher risk for hospitalization and death from a viral illness.

Segment Analysis

The sensor segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated into the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period. Globally, diabetes mellitus has been of wide concern with its high global prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. Continuous glucose monitoring has become a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients. According to a research study by Ziyi Yu et al., published in IOP Science Journal March 2021, a large variety of promising glucose-sensing technologies from traditional electrochemical-based glucose sensors to novel optical and other electrical glucose sensors has been developed which shows a positive impact on the market growth.

Geographical Analysis

North America region holds the largest market share of the global continuous glucose monitoring market

North America has the largest market share in the forecast period. Some of the factors that are driving the market growth in the North American region include increasing cases of diabetes and efforts taken by the national government to manage the disease at a larger level along with rising adoption of alternate and novel devices and the presence of key market players. In April 2020, Abbott Laboratories and Dexcom, Inc. received United States Food and Drug Administration (FDA) approval to use continuous glucose monitoring in United States hospitals for Coronavirus-affected people. Dexcom began shipping continuous glucose monitoring devices to hospitals in April 2020 and plans to make 100,000 sensors to sell to hospitals at a low cost and planned to donate 10,000 phones and continuous glucose monitoring readers to hospitals for scanning those sensors.

As per Diabetes Canada, in 2020, there were around 11 million Canadians with diabetes or prediabetes. As the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of continuous glucose monitoring devices sold will also follow. Thus, owing to the above factors it is expected to drive the market growth over the forecast period.

Competitive Landscape

The continuous glucose monitoring market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Dexcom, Inc., A. Menarini Diagnostics s.r.l, Echo Therapeutics, Inc., GlySens Incorporated, Johnson and Johnson, Medtronic Plc, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd, Medtrum Technologies, Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the continuous glucose monitoring market globally. For instance, in June 2020, Menarini Diagnostics has launched GlucoMen Day CGM, an innovative digital patch, wearable for fourteen days in a row, which monitors blood glucose and shows results directly on the smartphone.

Abbott Laboratories

Overview:

Abbott Laboratories is a U.S. health care company. The Company operates through four segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices.

Product Portfolio:

FreeStyle Libre 2: FreeStyle Libre 2 is a sensor-based glucose monitoring system that comes with a reader and a sensor. The sensor is applied to the back of the upper arm and can be worn for up to 14 days.

Why Purchase the Report?

Visualize the composition of the global continuous glucose monitoring market segmentation by component, end-user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global continuous glucose monitoring market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global continuous glucose monitoring market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global continuous glucose monitoring market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Continuous Glucose Monitoring Market- By Component

Transmitter

Receiver

Sensor

Insulin pumps

Others

Global Continuous Glucose Monitoring Market- By End User

Diagnostics Centers

ICUs

Home Healthcare

Global Continuous Glucose Monitoring Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global Continuous Glucose Monitoring Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Continuous Glucose Monitoring Market-Market Definition and Overview

3. Global Continuous Glucose Monitoring Market- Executive Summary

  • 3.1. Market Snippet By Component
  • 3.2. Market Snippet By End User
  • 3.3. Market Snippet by Region

4. Global Continuous Glucose Monitoring Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Continuous Glucose Monitoring (CGM) Devices
      • 4.1.1.2. Growing Cases of Diabetes
    • 4.1.2. Restraints:
      • 4.1.2.1. Inconsistency of Medicare Reimbursement
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Continuous Glucose Monitoring Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Continuous Glucose Monitoring Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Continuous Glucose Monitoring Market- By Component

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component Segment
    • 7.1.2. Market Attractiveness Index, By Component Segment
  • 7.2. Transmitter*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Receiver
  • 7.4. Sensor
  • 7.5. Insulin pumps
  • 7.6. Others

8. Global Continuous Glucose Monitoring Market- By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Diagnostics Centers*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. ICUs
  • 8.4. Home Healthcare

9. Global Continuous Glucose Monitoring Market- By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Global Continuous Glucose Monitoring Market- Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Global Continuous Glucose Monitoring Market- Company Profiles

  • 11.1. Abbott Laboratories*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Dexcom, Inc.
  • 11.3. A. Menarini Diagnostics s.r.l
  • 11.4. Echo Therapeutics, Inc.
  • 11.5. GlySens Incorporated
  • 11.6. Johnson and Johnson
  • 11.7. Medtronic Plc
  • 11.8. Senseonics Holdings, Inc.
  • 11.9. F. Hoffmann-La Roche Ltd
  • 11.10. Medtrum Technologies, Inc.

LIST NOT EXHAUSTIVE

12. Global Continuous Glucose Monitoring Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us